Viemed Healthcare
Viemed Healthcare's revenue rose 20.5% to $270 million in fiscal 2025. Its operating margin was 8.5%, up from 8.0% a year earlier. Free cash flow was $12 million, up 805.2%. It paid out $13 million in dividends and buybacks, 111% of free cash flow.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Viemed Healthcare does
Viemed Healthcare provides home medical equipment and in-home healthcare services in the United States, with a focus on breathing, chronic care and women's health. Patients are treated at home by clinicians instead of in hospitals. It serves patients in all 50 states.
Most of its equipment is provided through monthly rental arrangements. Its services include home ventilators, BiPAP and CPAP machines (devices that help people breathe), oxygen therapy, percussion vests, in-home sleep apnea testing and treatment, and care for neuromuscular patients and for people with chronic obstructive pulmonary disease (COPD). It also supplies breast pumps and lactation products and runs a healthcare staffing business for outside healthcare institutions. It expects respiratory care, including home ventilation, to stay a significant part of its revenue. It depends on a few sources of reimbursement, including Medicare, and says it competes with companies that have longer histories and more resources.
Viemed is a holding company incorporated in British Columbia, with its main office in Lafayette, Louisiana. As of December 31, 2025, it employed 401 licensed respiratory therapists, about 29% of its employees.
Its biggest risks, as it describes them
- Cuts to reimbursement rates, or to coverage by payors such as Medicare, could hurt profits.
- It relies on only a few sources of reimbursement, which could delay payments and affect cash flow.
- A new Medicare coverage policy sets medical necessity criteria for home non-invasive ventilation.
- It depends on key suppliers for equipment, and supply interruptions could reduce revenue.
- It competes with companies that have longer operating histories and greater resources.
Income statement
From fiscal 2018 to 2025, earnings per share grew 6.4% a year and net income 6.6% a year, as new shares raised the share count by 3% and diluted each share's earnings.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 28 | 17 | 13 | 18 | 14 |
| Debt incl. finance leases | 6 | 0 | 8 | 4 | 12 |
| Net debt (negative means net cash) | −23 | −17 | −5 | −14 | −1 |
| Net debt to EBITDA | −1.0x | −0.7x | −0.1x | −0.3x | −0.0x |
| Debt to equity | 0.1x | 0.0x | 0.1x | 0.0x | 0.1x |
| Interest coverage | 33.0x | 35.7x | 16.8x | 18.8x | 26.3x |
| Current ratio | 2.7x | 2.1x | 1.2x | 1.4x | 1.2x |
| Quick ratio | 2.5x | 1.9x | 1.1x | 1.3x | 1.1x |
Cash flow
Projections
Project Viemed Healthcare's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought Viemed Healthcare shares on the open market, and 3 insiders sold $1.6 million.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jun 25, 2026 | William FrazierChief Medical Officer, Director | Sold | 10,000 | $11.72 | $117,200 | Form 4 |
| Jun 24, 2026 | Timothy SmokoffDirector | Sold | 20,000 | $11.50 | $229,967 | Form 4 |
| Mar 20, 2026 | Michael MoorePresident | Sold | 65,000 | $8.77 | $570,050 | Form 4 |
| Mar 19, 2026 | Michael MoorePresident | Sold | 40,232 | $9.21 | $370,537 | Form 4 |
| Mar 18, 2026 | Michael MoorePresident | Sold | 31,570 | $9.42 | $297,389 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 6 of 9 | 5 of 9 | 5 of 9 |
| Rule of 40 | 42.3% | 23.1% | 24.9% |
| Altman Z'' | 5.48 | 6.10 | 5.41 |
| Accruals ratio | −25.7% | −16.8% | −19.7% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Pass | Pass | Pass |
| Cash from operations is positive | Pass | Pass | Pass |
| Return on assets rose | Pass | Fail | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Fail | Pass | Fail |
| Current ratio rose | Fail | Pass | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Pass | Fail | Fail |
| Revenue rose relative to assets | Pass | Fail | Pass |
| F-score | 6 of 9 | 5 of 9 | 5 of 9 |
Compare
Put Viemed Healthcare side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Viemed Healthcare | FY25 | 20.5% | 8.5% | 4.4% | 12.4% | −0.0x | 5 | |
| Schrödinger | FY25 | 23.3% | −65.2% | 4.9% | — | — | — | Compare |
| DocGo | FY25 | −47.7% | −55.3% | 9.3% | −84.6% | — | 3 | Compare |
| Fulgent Genetics | FY25 | 13.8% | −28.2% | −38.5% | −8.7% | — | 4 | Compare |
| Castle Biosciences | FY25 | 3.7% | −12.4% | 8.2% | −19.1% | — | 4 | Compare |
8 years of figures
| Fiscal year | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | 64 | 80 | 131 | 117 | 139 | 183 | 224 | 270 |
| Revenue growth | — | 24.5% | 63.6% | −10.8% | 18.6% | 31.8% | 22.5% | 20.5% |
| Gross profit | 48 | 56 | 80 | 73 | 85 | 113 | 133 | 156 |
| Research and development | 0 | 1 | 1 | 2 | 3 | 3 | 3 | 3 |
| Operating income | 10 | 9 | 27 | 12 | 8 | 14 | 18 | 23 |
| Net income | 10 | 8 | 32 | 9 | 6 | 10 | 11 | 15 |
| Diluted EPS (US$) | 0.24 | 0.21 | 0.78 | 0.22 | 0.16 | 0.25 | 0.28 | 0.37 |
| Diluted shares (millions) | 40 | 40 | 40 | 41 | 40 | 40 | 41 | 41 |
| Cash flow | ||||||||
| Cash from operations | 22 | 19 | 35 | 22 | 28 | 45 | 39 | 52 |
| Capital expenditure | 6 | 13 | 13 | 20 | 23 | 26 | 38 | 40 |
| Free cash flow | 16 | 6 | 22 | 3 | 5 | 19 | 1 | 12 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 2 | 2 | 0 | 0 | 10 | 0 | 0 | 13 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 29 | 3 | 26 |
| Stock-based compensation | 3 | 4 | 5 | 5 | 5 | 6 | 6 | 9 |
| Balance sheet at fiscal year end | ||||||||
| Cash and short-term investments | 10 | 13 | 31 | 28 | 17 | 13 | 18 | 14 |
| Debt incl. finance leases | 0 | 9 | 8 | 6 | 0 | 8 | 4 | 12 |
| Total assets | 54 | 83 | 113 | 118 | 117 | 155 | 177 | 199 |
| Total liabilities | 21 | 39 | 31 | 23 | 20 | 41 | 44 | 56 |
| Shareholders' equity | 33 | 44 | 82 | 95 | 97 | 114 | 131 | 142 |
| Margins and ratios | ||||||||
| Gross margin | 74.1% | 69.8% | 61.0% | 62.7% | 61.0% | 61.6% | 59.4% | 57.5% |
| Operating margin | 15.6% | 11.0% | 20.4% | 9.9% | 5.9% | 7.8% | 8.0% | 8.5% |
| Net margin | 14.8% | 10.6% | 24.0% | 7.8% | 4.5% | 5.6% | 5.0% | 5.5% |
| Free cash flow margin | 25.2% | 7.1% | 16.8% | 2.4% | 3.5% | 10.4% | 0.6% | 4.4% |
| Rule of 40 (growth + FCF margin) | — | 31.6% | 80.4% | −8.5% | 22.1% | 42.3% | 23.1% | 24.9% |
| Return on capital | — | 27.7% | 54.6% | 12.9% | 7.5% | 10.8% | 11.1% | 12.4% |
| Return on equity | — | 22.4% | 50.3% | 10.3% | 6.5% | 9.7% | 9.2% | 10.9% |
| Return on assets | — | 12.5% | 32.3% | 7.9% | 5.3% | 7.5% | 6.8% | 7.9% |
| Net debt to EBITDA | −0.8x | −0.3x | −0.6x | −1.0x | −0.7x | −0.1x | −0.3x | −0.0x |